**National Survey of Variations in Practice in the Prevention of Surgical Site Infections in Adult Cardiac Surgery, United Kingdom & Republic of Ireland**

*Cardiothoracic Interdisciplinary Research Network\*, National Cardiac Benchmarking Collaborative1, Public Health England2.*

\* Cardiothoracic Interdisciplinary Research Network, Leicester Clinical Trials Unit, University of Leicester, Leicester, United Kingdom

1 National Cardiac Benchmarking Collaborative; <https://www.ncbc-nhs.org/>

2 National Infection Service, Public Health England, 61 Colindale Avenue, London, NW9 5EQ, United Kingdom

**Authors**

Dincer Aktuerk\*, Jason M Ali\*, Abdul Badran\*, Damian Balmforth\*, David Bleetman\*, Colin Brown\*, R Calanao\*, James Cartwright\*, Laura Casey\*, Lilian Chiwera\*, Daniel Fudulu\*, Megan Garner\*, George Gradinariu\*, Stephen Green1, Amer Harky\*, Pauline Harrington2, Azar Hussain\*, Sandra Hutton\*, Ee Phui Kew\*, Theresa Lamagni2, Mahmoud Loubani\*, Krishna Mani\*, Jennifer Martin\*, Melissa Rochon\*, Rebecca Miles1, Nader Moawad\*, Mirko Muretti\*, Gavin J Murphy\*, Guido M Olivieri\*, Ilene Paglinawan\*, Juan C Quijano-Campos\*, Victoria Rizzo\*, Susan Robertson\*, Luke J Rogers\*, Marius Roman\*, Karen Salmon\*, Julie Sanders\*, Shagorika Taludker\*, Judith Tanner\*, Ricky Vaja\*, Alicja Zientara\*

Authors are listed alphabetically. Individual roles, contributions and acknowledgments are listed in Appendix A.1

**Address correspondence**: Luke J Rogers & Ricky Vaja; email: [CIRNetwork@outlook.com](mailto:CIRNetwork@outlook.com)

**Word count**: 3,818

**Key words**: cardiac surgery, surgical site infection, prevention

**SUMMARY**

**Introduction**

Currently no national standards exist for the prevention of surgical site infection (SSI) in cardiac surgery. SSI rates range from 1% to 8% between centres. The aim of this study was to explore and characterise variation in approaches to SSI prevention in United Kingdom (UK) and Republic of Ireland (ROI).

**Methods**

Cardiac surgery centres were surveyed using electronic web-based questionnaires to identify variation in SSI prevention at the level of both institution and consultant teams. Surveys were developed and undertaken through collaboration between the Cardiothoracic Interdisciplinary Research Network (CIRN), Public Health England (PHE) and the National Cardiac Benchmarking Collaborative (NCBC) to encompass routine pre-, intra- and postoperative practice.

**Results**

Nineteen of 38 centres who were approached provided data and included responses from 139 consultant teams. There was no missing data from those centres that responded. The results demonstrated substantial variation in over 40 aspects of SSI prevention. These included variation in SSI surveillance, reporting of SSI prevention rates to external bodies, utilisation of SSI risk prediction tools, and the implementation of additional precautions such as sternal support devices and gentamicin impregnated sponges.

**Conclusion**

Measured variation in SSI prevention in cardiac centres across the UK and ROI is evidence of clinical uncertainty as to best practice, and has identified areas for quality improvement as well as knowledge gaps to be addressed by future research.

**INTRODUCTION**

Surgical site infection (SSI) is the most significant healthcare-associated infection affecting surgical patients [1]. In England, the incidence of SSI at 30-days is 8.6% for coronary artery bypass grafting (CABG) and 2.2% for non-CABG operations [2]. SSIs following cardiac surgery can add an additional 2 weeks’ stay to a patient’s in-hospital care, increase their likely readmission to hospital six-fold, and require extended outpatient follow-up and reoperation [3, 4]. These events have significant resource implications and the costs of treating post-cardiac surgery SSI in the United Kingdom (UK) are estimated to be £15 million per annum [3].

SSIs are often preventable. It has been estimated that there is a 39% to 55% potential for a significant reduction in rates of SSI through multifaceted interventions [5]. However, the certainty of the evidence to support these interventions is low, as has been acknowledged both by the 2019 National Institute for Health and Care Excellence (NICE) guidance for SSI prevention [6], and the Global Guidelines for the Reduction of Surgical Site Infection published by the World Health Organisation [7]. Evidence gaps lead to clinical uncertainty and variations in care. Currently, there are no national standards of care specific to the prevention of cardiac SSIs in UK cardiac centres. We sought to determine if existing uncertainty is reflected by variation in SSI prevention practice occurs across UK and Republic of Ireland (ROI) cardiac surgery centres. These data will provide a benchmark for quality improvement strategies to reduce SSI rates, as well as evidence of equipoise to justify future research.

**METHODS**

This study was devised and delivered by the Cardiothoracic Interdisciplinary Research Network (CIRN), a research collaborative established by cardiothoracic surgery trainees [8], along with nurses and allied health professionals, that provides key infrastructure for the design and delivery of high-quality patient focused clinical research in people undergoing cardiothoracic surgery. According to the NHS Health Research Authority, this study is not considered research as defined by the UK Policy Framework for Health and Social Care Research. Therefore, ethical committee approval was not required.

*Sample & Setting*

The surveys were issued to all 38 cardiac surgery centres in the UK (n = 35) and ROI (n = 3).

*Survey Design*

Surveys were developed by a Cardiothoracic Interdisciplinary Research Network (CIRN) steering committee. To identify variables of interest, the work drew primarily on four national sources: the National Institute for Health and Care Excellence (NICE) SSI guidance, the Department of Health (DH) High Impact Intervention care bundle to prevent SSI [9], a Cochrane review of measures to reduce SSI following cardiac surgery [10], and a 2017 NCBC survey of organisational SSI surveillance strategies. Each source was methodically reviewed and individual interventions relevant to cardiac surgery were extracted. In addition, current regulatory standards upheld by the Care Quality Commission (CQC) such as Regulation 20: Duty of candour [11] were included where appropriate. This regulation ensures that care providers are open and transparent with people who use the service in relation to care and treatment. After a full list of interventions and standards was compiled, corresponding survey response options were discussed by the CIRN steering committee and amended through regular teleconferences to ensure a standardised closed-question approach with corresponding measures.

In February 2019, the surveys were reviewed by stakeholders at the NCBC annual conference. Following feedback from senior representatives of 22 cardiac centres including 35 cardiac surgeons, anaesthetists, nurses and managers the questionnaires were finalised. Two surveys were developed. The first **Trust Survey** compromised 13 questions aimed to capture organisational and policy level data across institutions, in the UK commonly referred to has Hospital Trusts. This term has been used across centres in Scotland and ROI for ease. The second **Team Survey**, aimed to capture routine clinical practice centred around consultant surgeon teams and compromised 72 questions. Both surveys were translated into a bespoke online tool. The online version (Microsoft Forms, Office 365®) of the surveys were further reviewed and tested by the collaborative team members prior to roll out. The complete list of questions for the two surveys are listed in **Appendices B.1 and C.1**.

*Pilot Study*

To identify any technical, analytical or comprehension problems both surveys were piloted in May 2019 by 59 surgeons in 9 centres. There was 100% completion within 1-month. Following some minor grammatical changes to the wording all remaining cardiac hospitals in the UK and ROI were invited via the SCTS, CIRN and NCBC to take part.

*Survey Distribution & Data Collection*

The two surveys were launched in the UK and ROI in May 2019. Links to the online surveys were distributed via email to named recipients. Each centre was provided its own unique code know only to steering committee leads and each consultant was assigned their own unique identifier known only to local leads to ensure both anonymity of centre and consultant. Each participating centre had a lead identified through the CIRN, who had overall responsibility for data collation through consultation with the appropriate teams at their centre – including infection control, SSI surveillance and surgical teams. They were either a junior doctor and/or a nurse or allied health professional (AHP). A single **Trust Survey** was completed for each centre. **Team Surveys** were completed once for each adult cardiac consultant per centre. Reminders were sent via email and text message. For a period of one-month (July 2019) data were entered onto the online survey. A senior member (defined as the Clinical Lead, NCBC representative, Line Manager or interested Senior Consultant) was required to review and authorise each centres data prior to submission via the online survey. The online survey permitted final dataset submission only when all questions has been answered, thereby ensuring completeness.

*Data Storage & Governance*

All responses were collected and stored on a secure cloud-based server. Patient level data including identifiable information was not collected. This study was conducted in accordance with International Conference for Harmonisation of Good Clinical Practice (ICHGCP) guidelines and the Declaration of Helsinki (World Medical Association 2000) Research Governance Framework for Health and Social Care.

*Data analysis*

Simple descriptive analyses were performed. Data are presented as a percentage of respondents in a table and in graphical form when deemed appropriate.

**RESULTS**

***Responses***

The surveys were distributed to 38 hospitals in UK and ROI. Of these 19 agreed to participate (50% response rate for hospital level data). Surveys were completed by 139 consultant teams working at these hospitals from a potential sample size of 257 (54%). All surveys were completed in full, with no missing data. SSI rates reported at Trust level between January and December 2018 ranged from 1% to 9.9% (mean 3.6% ± SD 1.4).

***Hospital Trust Survey***

Trust level responses to questions on perioperative SSI prevention practices are listed in **Table I.** Centres reported which aspects of the DH/National UK High Impact Intervention bundle (2010/2011) [10] were routinely performed; of these screening for methicillin resistant *S. aureus* (MRSA) colonisation and hair removal with electric clippers were performed by all centres (19) (**Table I**). Preoperative showering and glucose control for diabetic patients was routinely performed in 18 centres (95%). Sixteen (84%) centres provided written information to patients on SSI prevention both pre- and postoperatively, with an additional two centres providing information only preoperatively. Four centres (21%) provided SSI video education.

Data on Trust SSI surveillance reporting is reported in **Table I and II**. Eighteen centres participated in external SSI monitoring. Twelve (63%) participated in national surveillance schemes run by Public Health England (PHE), Public Health Wales or Health Protection Scotland, eleven (58%) reported deep sternal SSI rates to National Institute for Cardiovascular Outcomes Research (NICOR), and eight (42%) participated in the Getting It Right First Time (GIRFT) SSI audit. SSI case definitions used to these external bodies varied. All centres reported SSI occurring within the primary admission and 18 (95%) centres included those requiring readmission. Eight (42%) included SSI diagnosed in the community (outpatient/GP), and eleven (58%) recorded superficial infections up to 30 days and deep incisional organ/space up to 1-year postoperatively. A confirmed diagnosis of mediastinitis was met with Regulation 20(2): Duty of candour (DoC) [11] in 7 (37%) centres.

***Team Survey***

*Care Bundles*

SSI care bundles were used routinely by 105 (76%) consultant teams, of which 92 (66%) reported care bundle implementation for all patients (**Table III**). Thirty (22%) consultant teams targeted SSI care bundle(s) to patients deemed at medium or high-risk of SSI and 17 (12%) targeted high-risk patients only. No standardised method was used to identify patients at greater risk of SSIs. Eighty-eight (63%) consultant teams reported using no scoring tool to determine SSI risk. Remaining teams used locally validated tools, including 21 (15%) centres which used the Brompton and Harefield Infection Score (BHIS), 15 (11%) the Barts-Surgical Infection Score (B-SIRS), and 9 (6.5%) that used the Surgical Site Infections (SSI) or National Nosocomial Infection Surveillance System (NNIS) risk index.

*Preoperative Diabetes Management*

HbA1c levels were routinely measured by 114 (82%) consultant teams in people with known diabetes (**Table IV**). Twenty-one (11%) reported testing no patients. In those screened, who had an abnormal result, optimisation of their diabetic treatment pre-surgery was reported by 100 (81%) teams. The use of perioperative sliding scale insulin varied. All patients with diabetes receiving sliding scale insulin for 68 (49%) consultant teams, only diabetic patients with abnormal blood glucose for 41 teams (30%), only diabetic patients on insulin for 18 teams (13%), and only those with elevated blood glucose regardless of whether they had diabetes or not for 6 teams (4.3%).

*Skin Decolonisation Prior to Surgery*

All 139 consultants recommend washing prior to surgery, with 100 (72%) consultant teams recommending washing the night before surgery and 106 (76%) on the day of surgery (**Table V**). One-hundred and thirty-nine (100%) teams routinely removed hair using electric clippers the day before surgery (44, 32%), the morning of surgery (67, 48%), in the anaesthetic room (19, 14%) or on the operating table (9, 7%). Hair was not routinely removed by two consultants. Hair was most commonly removed by ward staff for 90 (65%) consultants although 19 (14%) consultant teams delegated this to patients themselves or carers.

Products used for pre-surgery skin decolonisation included washing with chlorhexidine gluconate liquid (67, 48%) and Octenisan (46, 33%). Mupirocin (2%) nasal decontamination was used by 94 (68%) teams although an alternative bactericidal medication was used by 41 (29%) teams. In 62 (45%) teams, skin decolonisation with antimicrobial solution was restricted to those with a current, previous, or unknown, history of MRSA skin colonisation. Skin decolonisation with (chlorhexidine gluconate 4% or alternative) was targeted to high-risk patients by 15 (11%) consultant teams. Mouthwash (chlorhexidine gluconate 0.2%) was used in 29 (21%) consultant teams in patients with current, historical or an unknown history of MRSA, high-risk individuals only in 13 (9%) teams and 10 (7%) teams used no form mouthwash decolonisation.

*Antibiotic Prophylaxis*

The results for antimicrobial prophylaxis are reported in **Table VI**. Ninety-five (68%) consultant teams used a combination of at least two antimicrobials for SSI prophylaxis in CABG. The most frequently utilised antimicrobials in patients undergoing CABG with no allergies or known infection were flucloxacillin (88, 63%), gentamicin (79, 57%) and cefuroxime (39, 28%). The duration of antibiotic prophylaxis treatment ranged from 12 hours (15, 1%) through to 24 (92, 66%) and 48 hours (22, 16%) post anaesthetic induction. In patients undergoing valve surgery 118 (85%) teams utilised two antibiotics and 21 (15%) a single antimicrobial. Antimicrobial prophylaxis in patients undergoing valve surgery included gentamicin (101, 73%), flucloxacillin (88, 63%) and cefuroxime (42, 30%) most commonly. This was continued up to 24 hours postoperatively in 90 (65%) consultant teams, 21 teams (15%) continued up to 48 hours, and 3 (2%) teams continuing until the central line is removed.

*Theatre Specialisation*

Dedicated cardiac surgery theatres were available to 93 (67%) consultant teams whilst 31 (22%) were shared with thoracic surgery and another 15 (11%) shared with other surgical specialties. No centres had a dedicated theatre for infected cases and 26% (36) used laminar flow ventilation systems.

*Scrubbing Practices*

Chlorhexidine gluconate (75, 54%) or betadine (46, 33%) was used for surgeon hand washing/ skin decolonisation prior to surgery, with (24, 17%) of surgeons reporting no preference (**Table VII**). Single gloving was reported by 102 (73%) consultant teams, double gloving by 19 (14%) teams, and 18 (13%) double-gloving only in selected cases. In 26 (19%) teams glove changes occurred at specific operative times such as prior to handling of any prosthesis.

*Skin Preparation & Draping*

One hundred and nineteen (85%) consultant teams used chlorhexidine gluconate for skin preparation **(Table VIII)**. Chlorhexidine gluconate 2% was delivered via applicator (78, 56%) or bottle 26 (19%). Povidone iodine preparations were used by 15 (11%) consultant teams. One hundred and twenty-four teams (89%) reported using other skin preparations.

Eighty-four (60%) used at least two applications of skin preparation either as a pre-preparation in the anaesthetic room prior to transfer into the theatre suite or as double preparation in theatre prior to draping. This was left to air dry for > 2 minutes by 103 (74%) teams. Disposable drapes with additional adhesive drapes for the sternum were used by 126 (91%) and 133 (96%) teams respectively. Ioban, an iodophor impregnated additional adhesive drape was used routinely by 106 (76%), Opsite by 27 (19%), or no additional adhesive by 6 (4%) consultant teams. One hundred and twenty-one (87%) teams incised the skin with a scalpel blade and then used diathermy for subcutaneous tissues. Scalpel blade to bone was used by 10 (7.2%) whereas 8 (6%) reported using diathermy for the entire incision, including skin. Bone marrow haemostasis was routinely achieved with bone wax by 109 (78%) consultant teams with 18 (13%) using only diathermy. Eleven (8%) consultants did not use any specific technique for bone marrow haemostasis.

*Conduit Harvesting Techniques & Wound Closure*

Conduit harvesting was performed via open surgical technique by 84 (61%) teams, endoscopic harvesting by 45 (32%), or a bridging technique by 9 (7%) teams (**Table IX**). Radial artery harvest was performed via an open (121, 87%) or ‘no touch’ (52, 37%) techniques. Subcutaneous drains were routinely used following harvest of the radial artery and saphenous vein graft in 26 (19%) and 30 (22%) of consultant teams respectively. Compression bandages were applied to saphenous vein harvest sites for 24 hours by 94 (68%) teams and 48 hours by 43 (31%) teams. For radial artery harvest, the durations were 61% (85) for 24 hours and 9% (13) for 48 hours. Transparent woven island dressings (such as Opsite Post-op and Mepore) were applied immediately following completion of surgery by 76 (55%) teams. A wound visible dressing (for instance Opsite Post-op Visible) was used by 38 (27%) teams and a topical adhesive such as Dermabond was used by 9 (6%) teams.

*Sternal Wound Closure Technique*

Sternal wound closure used single wires according to weight (62, 45%), double wire technique or equivalent (37, 27%), or a standard number of wires regardless of weight (48, 35%) (**Table X**). In obese patients, sternal closure was achieved using a double wire technique with either two single wires or Mayo wires by 89 (64%) teams, standard single wires were used by 20 (14%), single wires according to weight by 18 (13%) and a combination of techniques by 12 (9%) teams which included three with ZipFix and two with Flexigrip. For the closure of the pre-sternal tissues, uncoated Vicryl was used for both closure of the muscle layer (104, 75%) and subcutaneous layer (113, 78%) and Monocryl for skin layer (108, 78%).

Local antibiotics were used for sternal closure by 32 (23%) teams. This included 18 (13%) gentamicin impregnated sponges, 9 (7%) antibiotic powder and 5 (4%) antibiotic solutions. Thirty-five (25%) used a Posthorax vest (11, 8%) or Cough lok (24, 17%) in high-risk or selected patients. Cardiac bras (such as BHIS bra) were routinely used in female patients by 15 (11%) consultant teams or in high-risk, selected individuals by 5 (4%) consultant teams; patient’s own or sports bra style was advised by 48 consultant teams (35%). No additional sternal support methods were used by 26 (19%) consultant teams.

**DISCUSSION**

**Main findings**

A survey of SSI prevention strategies in cardiac surgery centres in the UK and ROI demonstrated significant variation in care. Heterogeneity was noted in preoperative risk stratification, perioperative interventions, postoperative SSI surveillance, and reporting methods. No nationally standardised tool exists for preoperative SSI risk stratification purposes specific to cardiac surgery and this was reflected in the use of locally developed tools by 51 (37%) consultant teams and use of no tool at all in 88 (63%). Patients who are transferred from another hospital for “urgent” inpatient surgery often have a higher risk of SSI. In our survey only 35 (25%) of teams gave instructions to referring hospitals regarding decolonisation prior to transfer. This highlights a potential variation in care between those “urgent” patients requiring inpatient transfer and elective patients.

A dedicated wound surveillance individual or team only existed in 13 (68%) Trusts, only 11 (58%) Trusts provided wound surveillance clinics and 11 (58%) Trusts had no system in place to allow effective follow-up whether through photo at discharge, post-discharge questionnaire, telephone call, or other reporting systems.

There was low variability between centres for some preoperative SSI prevention interventions; all 19 centres that responded to the survey reported MRSA screening and hair removal with single-use electrical clippers, 17 centres (95%) reported preoperative showering and glucose control for diabetic patients in line with the High Impact Intervention – Care Bundle to prevent SSI published by the UK Department of Health and NICE [9]. In contrast,

**Clinical Importance**

This work reinforces the findings of Tanner et al [12] that surveillance definitions and data collection methods vary between centres and even more widely between countries [13]. The gold standard PHE SSI surveillance is only adhered to in a minority of cases with greatest participation in cardiac surgery being noted in patients undergoing CABG which is also associated with the largest decrease in *per cent* SSI rate over time [14]. It is therefore paramount that a comprehensive and agreed standard of wound surveillance is developed within each country and ideally internationally. This presents an opportunity to encourage participation across all cardiac surgical procedures in national surveillance (including post-discharge) [15] alongside strategies to engage patients themselves in SSI prevention such as ‘Photo at Discharge’ [16] and videos for SSI prevention for patients and carers recently endorsed by NICE.

At present centres which preoperatively stratify patient risk of SSI do so with a variety of risk prediction tools these have only been validated in local cardiac surgery populations; no nationally, validated tool exists. The approach of using routinely collected national SSI data would allow the development of a standardised tool applicable to the population of UK and ROI patients undergoing adult cardiac surgery thereby allowing preoperative identification of high-risk patients that may benefit from additional targeted interventions. Indeed, recent NICE guidance [6] has qualified recommendations on nasal and skin decolonisation, gentamycin-collagen implants and triclosan-coated sutures in cardiac surgery as a result of the uncertainties that exist in its implementation in all or targeted patients. This has primarily driven by the limited evidence available and a national strategy to prevent the emergence of multi-drug resistant organisms [10].

To ensure precision in both a future epidemiological study aiming to develop an SSI risk prediction tool and a clinical and cost effectiveness trial of targeted SSI prevention in individuals undergoing adult cardiac surgery it is essential that post-discharge PHE SSI surveillance is implemented using standardised metrics across all centres.

**Limitations**

The main strengths of the review include the iterative review of content by multiple groups to ensure that the surveys were comprehensive and efficient, the pilot survey to check accuracy and precision of the information collected, and the senior sign-off of the data that coupled with the 100% completion rate will have increased the accuracy of the data. The main limitation of the study is the self-determined nature of Trust and team involvement. This introduces the potential for non-response error that may impact on the generalisability of the findings. In mitigation, it may be surmised that the centres that declined to take part will have lower adherence to evidence based practice than responders. In which case their omission will not have produced elevated estimates of variation in practice. In addition, the intentional omission of any an analysis of association between variation in practice and centre specific SSI rates will have avoided the identification of spurious associations based on incomplete data. This was intentional, only randomised trials can demonstrate causal relationships between interventions and outcomes. The cross-sectional design of the survey only reflects practice only at the time in which it was completed. The 2019 NICE guidance on SSI prevention, published two months prior to the survey, may have longer-term effects on SSI care bundle implementation that will not have been measured. However, it is worth noting that the NICE guidance made only one specific recommendation for cardiac surgery patients, consideration of gentamicin collagen implants and this survey identified many more aspects of SSI prevention where there was important variability [6].

**Conclusion**

A cross-sectional survey of cardiac surgery centres in the UK and Ireland identified significant variation in the implementation of SSI prevention care bundles, both at institutional level and at the level of the individual consultant. There was also significant variation in SSI rates. Given the knowledge gaps identified in previous work, including contemporary treatment guidelines, we conclude that these results are evidence of clinical uncertainty. Together these findings support the implementation of quality improvement initiatives to standardise care as well as research that will address existing knowledge gaps.

**Appendices**

A.1 Authorship Contributions

B.2 Trust/Health Board Questionnaire

C.3 Team Questionnaire

**Acknowledgements**

This was a collaborative project between the Cardiothoracic Interdisciplinary Research Network (CIRN), Public Health England (PHE) and the National Cardiac Benchmarking Collaborative (NCBC). There were over 149 individuals who contributed to the delivery of this project. Individuals names and contributions are presented in Supplementary Data, Appendix A.1 The delivery of this project would not have been possible without the collaborative work of all these individuals.

**Conflict of Interest:** None declared

**Funding source:** Royal College of Surgeons Clinical Trials Programme and the Society of Cardiothoracic Surgery in Great Britain and Ireland. GJM is supported by the National Institutes for Health Research, the Leicester NIHR Biomedical Research Centre and British Heart Foundation Grants CH/12/1/29419, AA18/3/34220.

**References**

1. Suetens C, Latour K, Karki T, Ricchizzi E, Kinross P, Moro ML, et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. European communicable disease bulletin; 2018;23(46).
2. Lamagni T CK, Wloch C, Harrington P. The epidemiology of cardiac surgical site infection in England, 2018/19. 30th European Congress of Clinical Microbiology and Infectious Diseases; Paris, France: Clin Micriobiol Infect 2020.
3. Jenks PJ, Laurent M, McQuarry S, Watkins R. Clinical and economic burden of surgical site infection (SSI) and predicted financial consequences of elimination of SSI from an English hospital. J Hosp Infect. 2014;86(1):24-33.
4. Joshi V, Vaja R, Richens D. Cost analysis of gentamicin-impregnated collagen sponges in preventing sternal wound infection post cardiac surgery. Journal of Wound Care. 2016;25(1):22-5.
5. Schreiber PW, Sax H, Wolfensberger A, Clack L, Kuster SP. The preventable proportion of healthcare-associated infections 2005–2016: Systematic review and meta-analysis. Infect Control Hosp Epidemiol 2018;39(11):1277-95.
6. The National Institute for Health Care Excellene (NICE). Surgical site infections: prevention and treatment. NICE guidance [NG125] 2019.
7. World Health Organization (WHO). Global guidelines on the prevention of surgical site infection. 2016.
8. Aboelela SW, Larson E, Bakken S, Carrasquillo O, Formicola A, Glied SA, et al. Defining interdisciplinary research: conclusions from a critical review of the literature. Health Services Research 2007;42:1, Part I.
9. Department of Health (DH) High Impact Intervention: Care bundle to prevent surgical site infection. 2011.
10. Cardiothoracic Interdisciplinary Research Network. Interventions to prevent surgical site infection in adults undergoing cardiac surgery. Cochrane Systematic Review – Intervention – Protocol 2019; May
11. Health and Social Care Act 2008 (Regulated Activities) Regulations 2014.
12. Tanner J, Padley W, Kiernan M, Leaper D, Norrie P, Baggott R. A benchmark too far: findings from a national survey of surgical site infection surveillance. J Hosp Infect 2013;83(2):87-91.
13. Abbas M, de Kraker MEA, Aghayev E, Astagneau P, Aupee M, Behnke M, Bull A et al., Impact of participation in a surgical site infection surveillance network: results from a large international cohort study. J Hosp Infect 2019. 102(3): p. 267-276.
14. Public Health England (PHE) Surveillance of surgical site infections in NHS hospitals in England, April 2018 to March 2019. Public Health England Report. 2019.
15. Meijerink, H., Lamagni, T., Eriksen, H., Elgohari, S., Harrington, P., & Kacelnik, O. , Is It Valid to Compare Surgical Site Infections Rates Between Countries? Insights From a Study of English and Norwegian Surveillance Systems. Infect Control Hosp Epidemiol 2017; 38(2): p. 162-171.
16. Rochon M, Jenkinson S, Ramroop R, Deakin A, Rai P, Healy K, et al. Retrospective analysis of the Photo at Discharge scheme and readmission for surgical site infection following coronary artery bypass graft surgery. Journal of Infection Prevention 2018;19(6):270-6.

|  |  |  |
| --- | --- | --- |
| Table I. Perioperative SSI prevention practices, UK & Ireland 2019 - Trust Survey | % | Centres (n=19) |
| What aspects of the current DH/National UK high impact intervention bundle (2010/2011) does your hospital implement for cardiac surgery patients?  MRSA screening, and decolonisation as required  Hair removal with electric clippers  Preoperative showering  Glucose control for diabetic patients (< 11 mmol/L)  Prophylactic antibiotics within 60 minutes of skin incision  Iodophor-impregnated incise drapes  Regular hand hygiene audits  Skin preparation with alcohol-based solution of chlorhexidine  Interactive surgical dressing for 48 hours  Supplemental oxygen to in the early postoperative phase | 100%  100%  95%  95%  90%  74%  84%  63%  58%  84% | 19  19  18  18  17  14  16  12  11  16 |
| Does your cardiac centre use a policy(s) or guideline(s) for the prevention of cardiac surgical site infections?  Yes  No | 53%  47% | 10  9 |
| Which external bodies do you report your surgical site infection data to?  Public Health England/Public Health Wales/Health Protection Scotland  Society of Cardiothoracic Surgery (SCTS)/National Institute for Cardiovascular Outcomes Research (NICOR)  GIRFT SSI audit (Getting It Right First Time)  None | 63%  58%  42%  5% | 12  11  8  5 |
| Please indicate the frequency that reports relating to surgical site infections are sent to consultants?  Monthly  Quarterly  Not routinely provided | 37%  32%  32% | 7  6  6 |
| Are deep sternal wound infections recorded on the local incident reporting system?  Yes  No | 47%  53% | 9  10 |
| Is SSI data collected by a dedicated individual and/or team?  Yes  No | 68%  32% | 13  6 |
| Do you have a dedicated wound clinic available?  Yes  No | 58%  42% | 11  8 |
| What information is provided to patients/carers for SSI prevention?  Preoperative printed information – e.g. when and how to wash  Postoperative printed information – e.g. signs of SSI and who to contact  Video(s) on SSI prevention  Dedicated group teaching sessions (preoperative)  Dedicated group teaching sessions (postoperative)  Photo at discharge  Posters in ward showers and/or printed instructions | 95%  84%  21%  16%  42%  37%  47% | 18  16  4  3  8  7  9 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |

|  |  |  |
| --- | --- | --- |
| Table II. SSI surveillance, UK & Ireland 2019 - Trust Survey | % | Centres (n=19) |
| How are you detecting SSIs that are included in your annual rate?  Inpatient stay (primary admission)  Readmission to (primary) hospital for SSI  Outpatient/GP  Superficial SSI recorded up 30 days postoperatively  Deep and organ or space up to 1-year | 100%  95%  42%  58%  58% | 19  18  8  11  11 |
| How do you identify surgical site infections following discharge from hospital?  No system in place  Post-discharge questionnaire (PDQ) given to patients  GP practice reporting systems  Follow-up telephone calls for non-responders (patients) to PDQ  Follow-up telephone calls  District General Reporting systems | 58%  21%  21%  11%  32%  11% | 11  4  4  2  6  2 |
| Does the CABG SSI rate include?  Superficial incisional - sternal  Superficial incisional – leg  Superficial incisional - radial  Deep incisional – sternal  Deep incisional - leg  Deep incisional - radial  Organ/Space (e.g. mediastinitis/infective endocarditis) | 90%  84%  74%  100%  79%  79%  84% | 17  16  14  19  15  15  16 |
| Does a confirmed case of mediastinitis postoperatively trigger duty of candour requirements?  Yes  No | 37%  63% | 7  12 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |

|  |  |  |
| --- | --- | --- |
| Table III. Care Bundles and Risk Scores, UK & Ireland 2019 - Team Survey | % | Teams (n=139) |
| Does this consultant's team use a locally developed care bundle(s) for the prevention and/or management of cardiac surgery SSIs?  Yes  No | 77%  23% | 105  32 |
| Does the team use only one SSI care bundle or more than one?  None  1  2  3 or more | 23%  55%  1%  20% | 32  77  2  28 |
| How long has this current care bundle(s) been in use in your team?  No care bundle used  6 months – 1 year  1 – 2 years  > 2 years | 23%  6%  36%  35% | 32  8  50  49 |
| Which of the following patients are your care bundle(s) used on?  No care bundle used  All patients  Medium & high-risk patients  High-risk patients only | 23%  51%  17%  9% | 32  71  23  13 |
| What scoring system do you use to assess patient risk of getting an SSI?  No scoring system used  BHIS  Local B-SIR  SSI Risk Index (NNIS Risk Index)  Local Scoring System | 63%  15%  11%  6%  4% | 88  21  15  9  6 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |

|  |  |  |
| --- | --- | --- |
| Table IV. Diabetes Mellitus Management, UK & Ireland 2019 - Team Survey | % | Teams (n=139) |
| Which patients have their HbA1c levels routinely screened?  No screening  Known diabetic patients  Urgent inpatient referrals from own hospital  Urgent inpatient referrals from external hospital  Day of surgery admission (DOSA)  High-risk patients – no history of diabetes but at risk  Elective patients | 11%  82%  26%  26%  17%  32%  40% | 14  114  36  36  24  44  56 |
| If HbA1c levels abnormal preoperatively does diabetic optimisation occur prior to surgery?  HbA1c not checked   |  | | --- | | Yes | | No | | 11%  72%  17% | 15  100  24 |
| For confirmed diabetic patients, do you use a sliding-scale insulin during the peri-operative period  Yes – all diabetic patients  Yes – only those with abnormal blood sugars  Yes – only diabetic patients on insulin  Yes – only diabetic patients with abnormal blood sugars  No | 49%  4%  13%  30%  4% | 68  6  18  41  6 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |

|  |  |  |
| --- | --- | --- |
| Table V. Preoperative preparation for surgery by cardiac teams (n=139), UK & Ireland 2019 - Team Survey | % | Teams (n=139) |
| What is your recommended routine protocol for patients regarding the timing and frequency of pre-washing prior to surgery? (Exclude high risk patients and those with MRSA/MSSA)  Day of surgery  Night before surgery  Three days of washing prior to surgery  Five days of washing prior to surgery | 76%  72%  13%  1% | 106  100  18  1 |
| What product(s) do you ask patients to wash with on the day of surgery?  Bar soap (plain)  Liquid soap (plain)  Octenisan  Chlorhexidine gluconate liquid  Chlorhexidine gluconate wipes  No specific advice on which wash product to use | 4%  4%  33%  48%  6%  2% | 6  6  46  67  8  3 |
| What additional decolonisation measures do you use to reduce SSI risk? (Excluding standard MRSA/MSSA decolonisation measures)  Nasal decontamination Mupirocin 2% - current/history/unknown MRSA status  Nasal decontamination Other - current history/unknown/MRSA status  Nasal decontamination Mupirocin 2% - all patients (no screening)  Nasal decontamination Other - all patients (no screening)  Nasal decontamination Mupirocin 2% - selected patients (i.e. high-risk SSI)  Nasal decontamination Other - selected patients (i.e. high-risk SSI)  Mouthwash - current/history/unknown MRSA status  Mouthwash - selected patients (i.e. high-risk SSI)  No decolonisation | 27%  17%  30%  12%  10%  1%  21%  9%  7% | 38  24  42  17  14  2  29  13  10 |
| Do you routinely give instructions to referring hospitals regarding decolonisation of patients prior to transfer for surgery?  Yes  No | 25%  75% | 35  104 |
| How is body hair removed from the surgical sites prior to surgery?  Electric clipper  Hair is not routinely removed | 100%  0% | 139  0 |
| Who routinely removes patient hair?  Patient/carer  Ward staff  Theatre nursing staff  Surgical team  Surgical Care Practitioner (SCP)  No standard | 14%  65%  10%  4%  4%  3% | 19  90  14  6  6  4 |
| When is hair routinely removed?  Day before surgery  Morning of surgery  In the anaesthetic room  On the operating table | 32%  48%  14%  6% | 44  67  19  9 |
| How is body hair cleaned up following removal?  Patient showers after removal  Adhesive tape  Sticky mitts  Sheets and gown changed | 61%  12%  23%  4% | 85  17  32  5 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |

|  |  |  |
| --- | --- | --- |
| Table VI. Prophylactic Antibiotics, UK & Ireland 2019 - Team Survey | % | Teams (n=139) |
| How many antibiotics are used for prophylaxis in patients undergoing CABG (Excluding patients with allergies or ongoing infections)  Combination of two or more antibiotics  Single antibiotics only | 68%  32% | 95  44 |
| What antibiotic prophylaxis is used for patients undergoing CABG? (excluding patients with allergies and no ongoing infections)  Flucloxacillin  Gentamicin  Cefuroxime  Vancomycin  Teicoplanin  Ciprofloxacin | 63%  57%  28%  7%  25%  2% | 88  79  39  10  35  3 |
| What is the routine duration of prophylactic antibiotics in these CABG patients? (excluding patients with post-operative infections)  Up to 24 hours  12 hours  Up to 48 hours  Three doses  Single dose within 60 minutes of skin incision | 66%  11%  16%  1%  6% | 92  15  22  2  8 |
| How many antibiotics are used for prophylaxis in patients undergoing valve surgery (excluding patients with allergies or ongoing infections)  Combination of 2 or more antibiotics  Single antibiotic only | 85%  15% | 118  21 |
| What antibiotic prophylaxis is used for patients undergoing valve surgery? (Excluding patients with allergies or 1ongoing infections)  Flucloxacillin  Gentamicin  Cefuroxime  Vancomycin  Teicoplanin  Ciprofloxacin | 63%  73%  30%  7%  25%  2% | 88  101  42  10  35  3 |
| What is the routine duration of prophylactic antibiotics in valve patients? (excluding patients with infections)  Single dose < 60 minutes prior to skin incision  Up to 12 hours  Up to 24 hours  Up to 48 hours  Three doses  Until central line is removed | 6%  11%  65%  15%  1%  2% | 8  15  90  21  2  3 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |

|  |  |  |
| --- | --- | --- |
| Table VII. Surgeon scrubbing practice, UK & Ireland 2019 - Team Survey | % | Teams (n=139) |
| What hand scrub is used routinely by the consultant?  No preference  Chlorhexidine gluconate  Betadine  Iodine  Alcohol | 18%  54%  33%  9%  8% | 25  75  46  13  11 |
| What is your routine gloving practice?  Single gloving  Double gloving (all cases)  Double glove (selected cases e.g. high-risk)  Double glove until start of cardiopulmonary bypass then single  Glove change prior to handling prosthesis  Glove change after retractor placement  Glove change after sternal wires | 73%  14%  14%  1%  9%  7%  5% | 101  19  19  1  13  10  7 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |

|  |  |  |
| --- | --- | --- |
| Table VIII. Skin Preparation and Draping, UK & Ireland 2019 - Team Survey | % | Teams (n=139) |
| What skin-preparation is used routinely?  Chlorhexidine gluconate (0.5%) with 70% alcohol  Chlorhexidine gluconate (2%) with 70% alcohol BOTTLE  Aqueous povidone iodine  Povidone iodine in alcohol preparation  Chlorhexidine gluconate (2%) with 70% alcohol BATON  Chlorhexidine gluconate (4%) with 70% alcohol  Iodine in alcohol preparation  A combination of chlorhexidine gluconate and povidone products | 8%  19%  1%  11%  56%  1%  3%  1% | 11  26  1  15  78  2  4  2 |
| What are the number of applications of skin-prep routinely used?  Social wash in anaesthetic room prior to skin preparation in theatre  Social wash on theatre table prior to prepping  Patient ‘pre-prepped’ or ‘double-prepped’ (two applications)  One  Three or more (e.g. ‘Nordic approach’) | 3%  11%  60%  25%  18% | 4  15  83  35  25 |
| How do you dry the surgical site prior to draping?  Air dry < 1 min  Air dry > 2min  Gauze swab dry | 16%  74%  10% | 22  103  14 |
| What material do you use for draping?  Disposable drapes  Fabric drapes  Varies with operation  Both | 90%  8%  1%  1% | 126  11  1  1 |
| What additional adhesive do you use over the surgical site?  Ioban  Opsite  Ioban™ & Opsite  Ioban™ & InteguSeal  No adhesive | 72%  19%  3%  1%  4% | 100  27  4  2  6 |
| Do you routinely use locally delivered antibiotics on (non-infected) sternal wound?  No  Antibiotic solution  Collagen impregnated sponge  Antibiotic powder | 77%  4%  13%  7% | 107  5  18  9 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |

|  |  |  |
| --- | --- | --- |
| Table IX. Conduit Harvest, UK & Ireland 2019 - Team Survey | % | Teams (n=139) |
| For a routine CABG, what is your method of conduit harvest? (Vein)  Conventional open harvest  Bridging or similar technique  Open harvest (no touch technique)  Endoscopic harvest | 56%  7%  5%  32% | 78  9  7  45 |
| For a routine CABG, what is your method of conduit harvest? (Radial)  Conventional open harvest  Open harvest (no touch technique)  Endoscopic harvest | 50%  37%  13% | 69  52  18 |
| What wound dressing do you routinely use in the immediate post-operative period? (Vein and radial harvest site)  Transparent woven island dressing  Postoperative visible dressing  Tissue adhesive  Topical negative pressure wound dressing  Other | 71%  9%  6%  4%  11% | 99  12  8  5  15 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |

|  |  |  |
| --- | --- | --- |
| Table X. Sternal Wound Closure Technique and Support, UK & Ireland 2019 - Team Survey | % | Teams (n=139) |
| What do you routinely do for sternal closure?  Single wire according to weight – e.g. 1 wire/10Kg  Double wire/other technique  Standard number of wires for all patients regardless of weight  Cable Ties  Combination of two or more techniques | 43%  27%  35%  1%  4% | 63  38  49  1  6 |
| What do you routinely do for sternal closure in an obese patient?  Sternal wires according to weight – e.g. 1 wire/10Kg  Double wire/other technique  Standard number of wires for all patients regardless of weight  Sternal plate  Combination of two or more techniques  Mayo wires  Flexigrip  Wires and cable tires | 16%  60%  14%  1%  9%  1%  1%  2% | 22  83  19  1  13  1  1  3 |
| What suture material do you routinely use for sternal wound closure (Muscle Layer)  None  Vicryl (uncoated)  Antibiotic impregnated suture  PDS (uncoated)  Monocryl | 4%  75%  5%  15%  1% | 6  104  7  21  1 |
| What suture material do you routinely use for sternal wound closure (Subcutaneous layer)?  Vicryl (uncoated)  Antibiotic impregnated suture (Triclosan Plus)  PDS (uncoated)  Monocryl (uncoated) | 81%  5%  12%  1% | 113  7  17  2 |
| What suture material do you routinely use for sternal site closure (Skin)?  Monocryl (uncoated)  Vicryl (uncoated)  Antibiotic coated Monocryl  Antibiotic coated Vicryl  Surgical clips (staples)  Tissue adhesive  Other | 78%  9%  8%  2%  1%  1%  1% | 109  13  11  3  1  1  1 |
| What wound dressing do you routinely use in the immediate postoperative period?  Transparent woven island dressings  Postoperative visible dressings  Tissue adhesive  Topical negative pressure wound dressing  Other | 55%  27%  7%  1%  11% | 76  38  9  1  15 |
| What support wear do you provide/recommend for male patients?  No support advised  Chest support vest (all male patients)  Chest support vest (selected patients i.e high-risk)  Cough band or similar (all male patients)  Cough band or similar (selected patients i.e. high-risk) | 58%  0% 15% 7% 19% | 81  0  21  10  27 |
| What support do you provide/recommend for female patients?  No support advised  Cardiac bra (all patients)  Cardiac bra (selected patients i.e. high-risk)  Chest support vest (selected female patients i.e. high-risk)  Cough support band (all female patients)  Cough support band (selected female patients i.e. high-risk)  Sports bra  Patient’s own bra (style not specified) | 19%  11%  4%  8%  7%  17%  12%  23% | 26  15  5  11  10  24  16  32 |
| Please note, some questions allowed multiple options to be selected so may not add up to 100%. | | |